Logo

American Heart Association

  15
  0


Final ID: MP1489

Twelve-month Changes in Lipid Management among Veterans who worked with a Health Coach vs. those who did not in the Veterans Affairs Lipid Optimization Reimagined Quality Improvement (VALOR-QI) Program

Abstract Body (Do not enter title and authors here): Background: Lipid management is critical for reducing cardiovascular events among those with atherosclerotic cardiovascular disease (ASCVD). Barriers to lipid management are multifactorial, including process-level and patient-level factors, which may require a multipronged approach to address.

Aims: To evaluate lipid lowering therapy (LLT) use and LDL-C levels at baseline and 12 months among Veterans who worked with a health coach (HC) vs. those who did not in the Veterans Affairs Lipid Optimization Reimagined Quality Improvement (VALOR-QI) Program.

Methods: VALOR-QI is a national quality improvement collaboration between the US Department of Veterans Affairs (VA) and the American Heart Association (AHA) with the goal of improving lipid management among Veterans with ASCVD across 50 VA sites. While some sites focused on process-level approaches, others additionally had a HC work directly with Veterans, providing education on the importance of LLT and lifestyle modifications and coordinating referrals to local programs (e.g., Whole Health). Data were analyzed from Veterans with ASCVD and a baseline LDL-C ≥ 70 mg/dL who received care from a VALOR-QI provider during the program, had 12 months pass since their first visit, and had at least two lipid labs during that time. We investigated changes in LLT use and LDL-C in Veterans who worked with a HC vs. those who did not.

Results: Among Veterans included in the analysis, 2,093 worked with a HC [mean (SD) age 70 (9.8) years, 93% men, 64% white race], and 37,834 did not [mean (SD) age 70 (10) years, 93% men, 70% white race]. Both groups experienced improvements in LLT use and LDL-C levels, though Veterans who worked with a HC saw greater improvements in statin + additional LLT use (15% vs. 7%), LLT adherence (24% vs. 14%), percent meeting LDL-C goal <70mg/dL (40% vs. 31%), and mean LDL-C (-25.5 vs. -14.7 mg/dL).

Conclusion: Among US Veterans in VALOR-QI, both those who worked with a HC and those who did not saw improvements in LLT use and LDL-C at 12-month follow-up, although improvements in some metrics were greater in Veterans working with a HC.
  • Ward, Rachel  ( Department of Veterans Affairs , Boston , Massachusetts , United States )
  • Leesch, Tharen  ( American Heart Association , Rapid City , South Dakota , United States )
  • Pena, David  ( American Heart Association , Georgetown , Texas , United States )
  • Djousse, Luc  ( Department of Veterans Affairs , Boston , Massachusetts , United States )
  • Gaziano, John Michael  ( Department of Veterans Affairs , Boston , Massachusetts , United States )
  • Wellman, Helen  ( Department of Veterans Affairs , Boston , Massachusetts , United States )
  • Yel, Nedim  ( Department of Veterans Affairs , Boston , Massachusetts , United States )
  • Coleman-lopez, Mason  ( Department of Veterans Affairs , Boston , Massachusetts , United States )
  • Santos, Abigail  ( Department of Veterans Affairs , Boston , Massachusetts , United States )
  • Delgrande, Jen  ( Department of Veterans Affairs , Boston , Massachusetts , United States )
  • Fink, Abigail  ( Department of Veterans Affairs , Boston , Massachusetts , United States )
  • Colson, Kristin  ( American Heart Association , Boise , Idaho , United States )
  • Pan, Eddie  ( American Heart Association , Plano , Texas , United States )
  • Author Disclosures:
    Rachel Ward: DO have relevant financial relationships ; Other (please indicate in the box next to the company name):The VALOR-QI program is supported by Novartis Pharmaceuticals Corporation.:Active (exists now) | Tharen Leesch: DO NOT have relevant financial relationships | David Pena: DO NOT have relevant financial relationships | Luc Djousse: No Answer | John Michael Gaziano: No Answer | Helen Wellman: DO have relevant financial relationships ; Research Funding (PI or named investigator):Novartis:Active (exists now) | Nedim Yel: DO NOT have relevant financial relationships | Mason Coleman-Lopez: No Answer | Abigail Santos: DO have relevant financial relationships ; Other (please indicate in the box next to the company name):Employee on a project funded by Novartis Pharmaceuticals Company:Active (exists now) | Jen DelGrande: No Answer | Abigail Fink: No Answer | Kristin Colson: DO NOT have relevant financial relationships | Eddie Pan: DO NOT have relevant financial relationships
Meeting Info:

Scientific Sessions 2025

2025

New Orleans, Louisiana

Session Info:

Targeteing Lipid-Associated Cardiovascular Disease Risk

Sunday, 11/09/2025 , 09:15AM - 10:30AM

Moderated Digital Poster Session

More abstracts on this topic:
3-Minute Heart Health App: A Feasibility Study

Abdulkarim Iya, Metzger Joseph, Stovitz Steven, Van't Hof Jeremy

A Hospital-Wide Multidimensional Approach to Pediatric In-Hospital Cardiac Arrest Review: Early Identification and Prevention

Loeb Daniel, Collins Kelly, Ortega Karina, Dewan Maya

More abstracts from these authors:
Six-month Changes in Lipid Management in the Veterans Affairs Lipid Optimization Reimagined Quality Improvement (VALOR-QI) Program

Ward Rachel, Leesch Tharen, Peña David, Congdon Michelle, Burlison Kelly, Djousse Luc, Gaziano John Michael, Wellman Helen, Yel Nedim, Coleman-lopez Mason, Santos Abigail, Delgrande Jen, Fink Abigail, Colson Kristin, Pan Eddie

A Novel Approach to Manage Hypercholesterolemia: The Veterans Affairs Lipid Optimization Reimagined Quality Improvement (VALOR-QI) Program

Djousse Luc, Leesch Tharen, Pena David, Gaziano Michael, Ward Rachel, Wellman Helen, Yel Nedim, Santos Abigail, Delgrande Jen, Fink Abigail, Colson Kristin, Pan Eddie

You have to be authorized to contact abstract author. Please, Login
Not Available